全文获取类型
收费全文 | 1284篇 |
免费 | 77篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 9篇 |
妇产科学 | 27篇 |
基础医学 | 159篇 |
口腔科学 | 13篇 |
临床医学 | 93篇 |
内科学 | 356篇 |
皮肤病学 | 97篇 |
神经病学 | 26篇 |
特种医学 | 98篇 |
外科学 | 152篇 |
综合类 | 7篇 |
预防医学 | 39篇 |
眼科学 | 10篇 |
药学 | 74篇 |
肿瘤学 | 194篇 |
出版年
2023年 | 9篇 |
2022年 | 17篇 |
2021年 | 25篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 38篇 |
2017年 | 35篇 |
2016年 | 19篇 |
2015年 | 21篇 |
2014年 | 28篇 |
2013年 | 36篇 |
2012年 | 64篇 |
2011年 | 59篇 |
2010年 | 37篇 |
2009年 | 36篇 |
2008年 | 49篇 |
2007年 | 52篇 |
2006年 | 45篇 |
2005年 | 61篇 |
2004年 | 59篇 |
2003年 | 72篇 |
2002年 | 56篇 |
2001年 | 47篇 |
2000年 | 37篇 |
1999年 | 44篇 |
1998年 | 19篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 9篇 |
1992年 | 36篇 |
1991年 | 38篇 |
1990年 | 44篇 |
1989年 | 41篇 |
1988年 | 32篇 |
1987年 | 26篇 |
1986年 | 22篇 |
1985年 | 29篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1977年 | 3篇 |
1976年 | 8篇 |
1973年 | 3篇 |
1968年 | 2篇 |
1965年 | 3篇 |
排序方式: 共有1364条查询结果,搜索用时 15 毫秒
31.
We report an unexpected cause of a febrile patient with huge splenomegaly. A 32-year-old patient with fever and huge splenomegaly was admitted to our hospital. Diagnostic splenectomy revealed that the enlarged spleen adhered strongly to the abdominal organs. Pathologically, the splenic parenchyma showed no malignant cells, and the soft tissue adjacent to the splenic hilum showed a proliferation of fibroblastic or myofibroblastic spindle cells with fibrosis and lymphoplasmacytic infiltration. These findings lead to a diagnosis of peritoneal fibrosis, and an administration of 50 mg/day of prednisolone alleviated all the symptoms. The differential diagnosis of huge splenomegaly with fever usually includes hematolymphoid malignancies and infectious diseases; however, our case was diagnosed as idiopathic retroperitoneal fibrosis. Our case suggests that when we see patients with fever and huge splenomegaly, differential diagnosis should include retroperitoneal fibrosis. 相似文献
32.
Kosuke Tanaka Akiko Sasaki Hideto Egashira Shinichi Teshima Karen Kimura Takashi Nishino Tomohiko Tazawa Junichi Tasaki Chikamasa Ichita Sakue Masuda Kazuya Koizumi Makoto Kako 《Internal medicine (Tokyo, Japan)》2021,60(7):999
We herein report the definitive diagnosis of rectovaginal endometriosis in two cases. Case 1 involved a 46-year-old woman with abdominal pain and hematochezia. The diagnosis after the first and second examinations using lower gastrointestinal (GI) endoscopy was unclear. Differential diagnoses included mucosa-associated lymphoid tissue and colorectal cancer. The third lower GI endoscopy with a targeted biopsy, performed during menstruation, confirmed rectovaginal endometriosis. Case 2 involved a 38-year-old woman with hematochezia. Lower GI endoscopy during menstruation revealed rectovaginal endometriosis. When rectovaginal or bowel endometriosis is suspected, lower GI endoscopy and a targeted biopsy during menstruation can prevent unnecessary surgery. 相似文献
33.
Hosen N Teshima H Karasuno T Ujiie H Nakao T Yagi T Hatanaka K Kawamoto S Hiraoka A Nakamura H Masaoka T 《[Rinshō ketsueki] The Japanese journal of clinical hematology》1999,40(1):9-15
The frequency of infection in recipients of allogeneic bone marrow transplants (BMT) who received oral new quinolones (NQ) was compared with that in BMT recipients who were given oral vancomycin/tobramycin (V/T). Between 1984 and 1997, our hospital treated 79 patients with V/T and 90 patients with NQ. Number of febrile days, duration of intravenous antibiotics administration, and frequency of documented infections were statistically the same for both groups. However, the frequency of grampositive bacterial infections, especially staphylococcal infections, was slightly higher in patients receiving NQ than in patients receiving V/T (p = 0.12). Of the patients who received NQ, those who underwent unrelated donor BMT procedures were generally febrile for slightly longer periods than those who underwent related donor BMT procedures (p = 0.10). These results suggest that oral NQ is as effective as oral V/T for the prevention of serious gramnegative bacterial infections in patients who undergo BMTs. 相似文献
34.
Dan H Tani K Hase K Shimizu T Tamiya H Biraa Y Huang L Yanagawa H Sone S 《Rheumatology international》2003,23(6):271-276
To determine the significance of CD13/aminopeptidase N in collagen vascular diseases (CVD), we examined its activity and expression in sera and disease sites of patients with CVD. Significantly higher aminopeptidase activity was detected in bronchoalveolar lavage fluid from patients with interstitial lung diseases due to rheumatoid arthritis (RA), polymyositis/dermatomyositis (PM/DM), systemic sclerosis (SSc), and Sjögren's syndrome than from control subjects. Increased aminopeptidase activity and increased expression of CD13/aminopeptidase N protein were found in alveolar macrophages from CVD patients with interstitial lung diseases. Significantly higher aminopeptidase activity was detected in pleural effusions from patients with systemic lupus erythematosus (SLE) than in transudate effusions. The mean aminopeptidase activity in synovial fluids from RA patients was significantly higher than from patients with osteoarthritis. The mean value of serum aminopeptidase activity was significantly higher in patients with SLE, RA, SSc, and PM/DM than in normal subjects. This study suggests that the activity of CD13/aminopeptidase N, locally produced in the disease site, is a useful marker for CVD and that CD13/aminopeptidase N may have an important role in the pathogenesis of CVD. 相似文献
35.
36.
37.
Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Youko Suehiro Atsuhiko Hasegawa Tadafumi Iino Amane Sasada Nobukazu Watanabe Masao Matsuoka Ayako Takamori Ryuji Tanosaki Atae Utsunomiya Ilseung Choi Tetsuya Fukuda Osamu Miura Shigeo Takaishi Takanori Teshima Koichi Akashi Mari Kannagi Naokuni Uike Jun Okamura 《British journal of haematology》2015,169(3):356-367
Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type‐I (HTLV‐I)‐infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV‐I Tax‐specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti‐ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate‐ to high‐risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax‐specific CTL responses were observed with peaks at 16–20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide‐pulsed DC vaccine is a safe and promising immunotherapy for ATL. 相似文献
38.
39.
Yu Sawada Tetsuya Honda Sho Hanakawa Satoshi Nakamizo Teruasa Murata Yuri Ueharaguchi-Tanada Sachiko Ono Wataru Amano Saeko Nakajima Gyohei Egawa Hideaki Tanizaki Atsushi Otsuka Akihiko Kitoh Teruki Dainichi Narihito Ogawa Yuichi Kobayashi Takehiko Yokomizo Makoto Arita Motonobu Nakamura Yoshiki Miyachi Kenji Kabashima 《The Journal of experimental medicine》2015,212(11):1921-1930
Resolvin E1 (RvE1) is a lipid mediator derived from ω3 polyunsaturated fatty acids that exerts potent antiinflammatory roles in several murine models. The antiinflammatory mechanism of RvE1 in acquired immune responses has been attributed to attenuation of cytokine production by dendritic cells (DCs). In this study, we newly investigated the effect of RvE1 on DC motility using two-photon microscopy in a contact hypersensitivity (CHS) model and found that RvE1 impaired DC motility in the skin. In addition, RvE1 attenuated T cell priming in the draining lymph nodes and effector T cell activation in the skin, which led to the reduced skin inflammation in CHS. In contrast, leukotriene B4 (LTB4) induced actin filament reorganization in DCs and increased DC motility by activating Cdc42 and Rac1 via BLT1, which was abrogated by RvE1. Collectively, our results suggest that RvE1 attenuates cutaneous acquired immune responses by inhibiting cutaneous DC motility, possibly through LTB4-BLT1 signaling blockade.Following the well-known epidemiological study conducted in Northwest Greenland in the 1970s (Dyerberg et al., 1978), several clinical assessments have indicated that a diet rich in ω3 polyunsaturated fatty acids (PUFAs) has beneficial effects in various inflammatory diseases, including asthma, psoriasis, inflammatory bowel diseases, and rheumatoid arthritis (Horrobin, 1987). Although it remains unclear how ω3 PUFAs exert such antiinflammatory effects, recent studies have identified several derivatives of ω3 PUFAs that possess strong antiinflammatory effects (Serhan et al., 2008; Tull et al., 2009). Resolvin E1 (RvE1) is one such antiinflammatory lipid mediator.RvE1 is known to exert its actions through two receptors, BLT1 and ChemR23 (Arita et al., 2007). RvE1 binds to BLT1, a G protein–coupled receptor for leukotriene B4 (LTB4), and inhibits BLT1 signals (Arita et al., 2007). In addition, RvE1 exhibits an agonistic activity toward ChemR23 (Arita et al., 2007), a G protein–coupled receptor for chemerin. The antiinflammatory effects of RvE1 have been demonstrated in acute innate immune inflammation, such as peritonitis (Arita et al., 2007) and colitis (Arita et al., 2005b). In these models, RvE1 exerted its antiinflammatory effects by inhibiting neutrophil infiltration into the inflammatory foci through a blockade of LTB4-BLT1 signaling in neutrophils (Haas-Stapleton et al., 2007). In contrast, few studies have been conducted on the effect of RvE1 on acquired immune responses, in which DCs and T cells play major roles in the development. In these studies, the attenuated cytokine production, such as IL-12 and IL-23, from DCs is considered as the major mechanism by which RvE1 exerts the antiinflammatory effects (Arita et al., 2005a; Haworth et al., 2008). However, the effect of RvE1 on DC motility has not been investigated in the context of acquired immunity.In the peripheral tissues such as the skin, DCs migrate in an amoeboid movement that requires actin polymerization via activation of the Rho family of small GTPases, such as Cdc42, Rac, and Rho A (Lämmermann and Germain, 2014). In acquired immunity such as contact hypersensitivity (CHS), upon uptake of foreign antigens, DCs migrate to the draining LNs (dLNs) via lymphatic vessels to establish sensitization by inducing the antigen-specific T cell differentiation (Honda et al., 2013). In elicitation, DC migration to form DC–T cell clustering is required for efficient antigen presentation in situ (Natsuaki et al., 2014). Thus, active DC motility is an essential factor for acquired immunity.In this study, we investigated the effects and underlying mechanisms of RvE1 on DC motility using a CHS model, which is a prototype of delayed-type hypersensitivity in the skin mediated by IFN-γ (Mori et al., 2008; Honda et al., 2013). RvE1 inhibited cutaneous DC migration into the dLNs and suppressed antigen-specific T cell induction in the sensitization phase. In addition, live imaging analysis revealed that RvE1 inhibited cutaneous DC motility and cluster formation in the skin, which subsequently attenuated activation of effector T cells in the skin in the elicitation phase of CHS. Intriguingly, LTB4 induced actin filament reorganization in DCs and increased DC motility by activating Cdc42 and Rac1 via BLT1, which was abrogated by RvE1. These results suggest that RvE1 exerts its antiinflammatory effects in cutaneous acquired immunity by inhibiting DC motility, possibly through an LTB4-BLT1 signaling blockade. 相似文献